Clinical trial · Observational
KidneyCare Cohort Study (KCC-S)
KidneyCare Cohort Study: Biologic Interrogation of Sarcopenia in Patients With Renal Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research study aims to learn how lifestyle factors (e.g., obesity) impact the risk of developing kidney cancer and impact survival after nephrectomy (removal of a kidney). The study team's long-term goals are to learn: 1) How to improve treatment success in future patients by tailoring therapies to each patient's unique biology; and 2) What future patients can do to improve their health after diagnosis. To this end, the study team will collect samples (such as blood and extra tissue from surgery) from patients and store and test these samples. The study team also asks patients about their health behaviors (e.g., diet and physical activity) and well-being before their diagnosis and afterwards by filling out questionnaires.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1
- description
- * Will provide blood, urine, and stool samples as well as CT-derived body composition and performance status assessments during the baseline and follow-up study visits. * Will provide tissue samples (kidney, fat, omentum, muscle) during cancer surgery. * Will provide follow-up questionnaires.
- label
- Cohort 2
- description
- * Will provide blood, urine, and stool samples as well as CT-derived body composition during the baseline study visit. * Will provide tissue samples (kidney, fat, omentum, muscle) during cancer surgery. * Will provide CT-derived body composition during follow-up.
Primary outcomes (1)
- measure
- Percent of Scheduled Assessments Completed
- timeFrame
- End of Participation (60-months post-surgery)
- description
- Feasibility of the study will be assessed by calculating a percentage of scheduled body composition, performance status measurements, performance status questionnaires and biospecimen collections completed.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Renal Cell Cancer (RCC) stage I-IV * Undergoing radical nephrectomy (entire kidney resection) or partial nephrectomy * Patients with or without prior systemic therapy for renal cell carcinoma and \> 1 year from systemic therapy for other non-cutaneous malignancy * Cytoreductive nephrectomy (nephrectomy in the setting of limited metastatic disease) Exclusion Criteria: * Does not consent to tissue collection * Patients with only an MRI abdomen/pelvis within 4 months of surgery will be excluded * Known biopsy-proven non-clear cell RCC
References
Publications (0)
Data not yet available